CLLS News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

CL

Mkt Cap

$104.8M

Volume

81.07K

Next Earnings

November 6th

Chart Earnings News About Insider Filings

Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law FirmCellectis S.A. announced on September 14, 2026, that it would discontinue CAR-T cell therapy development (lasme-cel and eti-cel) to prioritize in vivo gene editing therapies, citing limited cash resources. The announcement triggered a 40.97% stock price decline, prompting a securities fraud investigation by Glancy Prongay Wolke & Rotter LLP on behalf of affected shareholders.GlobeNewswire Inc. · Oct 15, 2026

Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. CruzThe Law Offices of Frank R. Cruz is investigating Cellectis S.A. for potential securities law violations following the company's September 14, 2026 announcement to discontinue CAR-T cell therapies (lasme-cel and eti-cel) and prioritize in vivo gene editing therapies due to limited cash resources. The announcement triggered a 40.97% stock price decline, causing investor losses.GlobeNewswire Inc. · Oct 14, 2026

CLLS INVESTOR ALERT: Investigation of Cellectis S.A. Announced by Holzer & Holzer, LLCLaw firm Holzer & Holzer, LLC announced an investigation into whether Cellectis S.A. complied with federal securities laws following the company's September 14, 2026 announcement to exit development of lasme-cel and eti-cel. The announcement triggered a stock price decline, prompting the firm to seek investors who suffered losses to discuss potential legal action.GlobeNewswire Inc. · Sep 17, 2026

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market Set for Strong Growth Through 2036, Driven by Next-Generation Innovation and Expanding Patient AccessThe CAR-T cell therapy market for acute lymphoblastic leukemia (ALL) is projected to grow at a 6.8% CAGR from 2026 to 2036, reaching from $300 million in 2025. The market is driven by approved therapies like KYMRIAH, TECARTUS, and AUCATZYL, with emerging innovations including allogeneic platforms and CD7-targeting therapies. Key challenges include relapse rates, manufacturing complexity, and toxicity management, while opportunities exist in earlier treatment lines and off-the-shelf platforms.GlobeNewswire Inc. · Sep 16, 2026

Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business UpdateCellectis, a clinical-stage biotechnology company specializing in gene editing and CAR T cell therapies, announced it will host a conference call and webcast on September 14, 2026 to provide a business update. The company will offer both English and French-language sessions with details on dial-in numbers and webcast links provided.GlobeNewswire Inc. · Sep 11, 2026

Cellectis organise une conférence téléphonique et un webcast le 14 septembre pour présenter un point d’activitéCellectis, a clinical-stage biotechnology company specializing in gene editing, announced it will hold a conference call and webcast on September 14, 2026, to provide an activity update. The event will be held in both English (8:00 AM NY time) and French (9:00 AM NY time) with dial-in numbers and webcast links provided for participants.GlobeNewswire Inc. · Sep 11, 2026

Unlocking Opportunity: Dominate the Market of CAR/TCR/TIL Therapies in Oncology with Confidence. See Exactly How Gilead, Cellectis, MediGene, GenScript, and CARsgen Are Positioned to Win Through 870+ RivalsResearchAndMarkets.com released a comprehensive analytical tool tracking CAR/TCR/TIL therapies in oncology, monitoring 870+ organizations and 2,370+ drugs across the pipeline. The tool provides competitive intelligence on leading developers including Gilead Sciences, Cellectis, MediGene, GenScript, and CARsgen Therapeutics, with 236 new therapies added in 2024/25 and over 1,700 BD&L contacts for partnership opportunities.GlobeNewswire Inc. · Sep 7, 2026

Cellectis présente les résultats finaux de phase 1 pour lasmé-cel et des résultats préliminaires pour éti-cel au congrès de l’EHA 2026Cellectis announced final Phase 1 data for lasme-cel, an allogeneic CAR-T therapy targeting CD22 in relapsed/refractory B-cell acute lymphoblastic leukemia, showing 100% overall response rate in the target population with manageable safety profile. The company also presented preliminary data for eti-cel, a dual-targeted CAR-T therapy against CD20 and CD22 in non-Hodgkin lymphoma, demonstrating 88% overall response rate at optimal dose with evidence that alemtuzumab exposure correlates with improved clinical outcomes.GlobeNewswire Inc. · Jun 11, 2026

Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 CongressCellectis announced final Phase 1 results from the BALLI-01 trial of lasme-cel, a CD22-directed allogeneic CAR-T therapy for relapsed/refractory B-cell acute lymphoblastic leukemia, showing 100% overall response rate in the target Phase 2 population with manageable safety profile. The company also presented preliminary data on eti-cel, a dual CD20/CD22 CAR-T for relapsed/refractory B-cell non-Hodgkin lymphoma, demonstrating 88% ORR in the optimal dose cohort. Both therapies are advancing to Phase 2 trials with first interim analyses expected in Q4 2026.GlobeNewswire Inc. · Jun 11, 2026

Allogene Arbitration Victory Pressures Cellectis Shares TuesdayAllogene Therapeutics won an arbitration against Cellectis regarding CAR-T therapy development rights, securing full control of cemacabtagene ansegedleucel in the U.S., EU, and U.K., while the tribunal rejected Cellectis's financial claims and allegations.Benzinga · Dec 16, 2025

CL

CLLSCellectis S.A. American Depositary Shares

CLLS

Pay with—

Available Balance0.00

Your PositionYou don't own any CLLS yet.

Related Tickers

Earnings